Rani Therapeutics Holdings, Inc. (RANI): Nasdaq/NYSE listing notice — Rani Therapeutics receives Nasdaq deficiency notice for MVLS below $50M

Rani Therapeutics Holdings, Inc.

Nasdaq notified Rani on May 1, 2025 that its Market Value of Listed Securities was below $50M for 30 consecutive business days.
Company has 180 calendar days, until October 28, 2025, to regain compliance by achieving MVLS >= $50M for 10 consecutive business days.
If noncompliance persists, Nasdaq may delist; Rani could appeal or apply to transfer to Nasdaq Capital Market.
Rani is considering actions to regain compliance but has not yet decided on a response.
There is no assurance of regaining compliance or meeting other listing criteria.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Rani Therapeutics Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A), 5810(c)(3)(C)

Exact text from the filing

May 1, 2025, Rani Therapeutics Holdings, Inc. (“Company”) received a letter (“Notice”) from the Nasdaq Stock Exchange LLC (“Nasdaq”), addressing a compliance deficiency under the Nasdaq Listing Rules. The letter notified of the deficiency with regard to Rule 5450(b)(2)(A), which requires a company whose securities are listed on The Nasdaq Global Market under the “Market Value Standard” to maintain a minimum Market Value of Listed Securities (an “MVLS”) of $50,000,000. The deficiency was caused by the Company’s MVLS having been below the minimum level for the prior 30 consecutive business days.

View on SEC.gov

Browse all listing & compliance notices →

Rani Therapeutics Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-064624

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.